Literature DB >> 29589526

ADAM Metalloproteinases as Potential Drug Targets.

Caterina Camodeca1, Doretta Cuffaro1, Elisa Nuti1, Armando Rossello1.   

Abstract

The ADAMs, together with ADAMTSs and snake venom metalloproteases (SVMPs), are members of the Adamalysin family. Differences in structural organization, functions and localization are known and their domains, catalytic or non-catalytic, show key roles in the substrate recognition and protease activity. Some ADAMs, as membrane-bound enzymes, show sheddase activity. Sheddases are key to modulation of functional proteins such as the tumor necrosis factor, growth factors, cytokines and their receptors, adhesion proteins, signaling molecules and stress molecules involved in immunity. These activities take part in the regulation of several physiological and pathological processes including inflammation, tumor growth, metastatic progression and infectious diseases. On these bases, some ADAMs are currently investigated as drug targets to develop new alternative therapies in many fields of medicine. This review will be focused on these aspects. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Metalloendopeptidases; adhesion molecules; ectodomain shedding; hydroxamate inhibitors; small molecules; zincbindingzzm321990group.

Mesh:

Substances:

Year:  2019        PMID: 29589526     DOI: 10.2174/0929867325666180326164104

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

Review 1.  Novel Approaches and Challenges of Discovery of Exosite Modulators of a Disintegrin and Metalloprotease 10.

Authors:  Dmitriy Minond
Journal:  Front Mol Biosci       Date:  2020-05-06

Review 2.  Developments in Carbohydrate-Based Metzincin Inhibitors.

Authors:  Doretta Cuffaro; Elisa Nuti; Felicia D'Andrea; Armando Rossello
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-10

Review 3.  Strategies to Target ADAM17 in Disease: From its Discovery to the iRhom Revolution.

Authors:  Matteo Calligaris; Doretta Cuffaro; Simone Bonelli; Donatella Pia Spanò; Armando Rossello; Elisa Nuti; Simone Dario Scilabra
Journal:  Molecules       Date:  2021-02-10       Impact factor: 4.411

4.  Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors.

Authors:  Doretta Cuffaro; Caterina Camodeca; Tiziano Tuccinardi; Lidia Ciccone; Jörg W Bartsch; Tanja Kellermann; Lena Cook; Elisa Nuti; Armando Rossello
Journal:  ACS Med Chem Lett       Date:  2021-10-08       Impact factor: 4.345

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.